Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential

Analyst UpgradesDec 16 09:10 ET

TD Cowen Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $165

Moomoo NewsDec 16 08:33 ET · Ratings

CCORF Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $167

Moomoo NewsDec 16 08:33 ET · Ratings

Wedbush Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $148

Moomoo NewsDec 16 08:33 ET · Ratings

Express News | Wedbush Reiterates Outperform on Neurocrine Biosciences, Maintains $148 Price Target

BenzingaDec 16 08:25 ET

Wedbush Reaffirms Their Buy Rating on Neurocrine (NBIX)

TipRanksDec 16 08:25 ET · Ratings